Blogs

IQ OQ PQ validation, standing for Installation Qualification, Operational Qualification, and Performance Qualification, is the internationally recognised framework for demonstrating that a tablet press machine is installed correctly, operates within specification, and consistently produces tablets meeting quality requirements.

Tablet compression machine problems are a significant source of production losses in pharmaceutical manufacturing, including rejected batches, unplanned downtime, wasted active pharmaceutical ingredient, and potential regulatory documentation failures.

India is the world's leading supplier of pharmaceutical equipment including tablet press machines, with manufacturers ranging from established names with decades of export experience to newer suppliers offering lower prices with limited support capability.

Bangladesh is one of the fastest-growing pharmaceutical export economies in the world, exporting to over 160 countries, but the end of its Least Developed Country status is removing the duty-free access that made Bangladeshi generics highly competitive and forcing manufacturers to upgrade to FDA-compliant automatic production equipment.

Nigeria currently imports approximately 70 percent of its pharmaceutical requirements and the government has set a target of achieving 70 percent local production by 2030, creating the largest single wave of pharmaceutical manufacturing investment in sub-Saharan Africa.

Saudi Arabia is the fastest-growing pharmaceutical manufacturing market in the Middle East, driven by Vision 2030 investment of USD 65 billion in healthcare and a government mandate to localise drug production and reduce pharmaceutical imports.

B tooling and D tooling are the two primary international standards for tablet press punches and dies, and choosing the wrong type for your machine or product can result in compatibility failures, tablet defects, and regulatory complications.

Rotary tablet compression machines almost always have an odd number of punches or stations, and this is not a random design choice. It is a deliberate engineering decision rooted in the physics of dynamic balancing.

Cancer and neurological drug tablets are life-critical medicines where dosing precision, zero-wastage of expensive APIs, and regulatory compliance are non-negotiable, making the tablet press machine a mission-critical piece of equipment.

Pharmaceutical tablet manufacturing moves through distinct stages, from early R&D and formulation work to pilot batches, scale-up, and finally full commercial production, and each stage requires a different type of tablet press machine.

Single rotary tablet press machines are ideal for medium-scale production, R&D, and operations where production volumes are between 50,000 and 3,00,000 tablets per hour.

In pharmaceutical tablet manufacturing, precision means every tablet contains exactly what the label says, not approximately, not close enough, but exactly. Deviation from target weight is a regulatory violation, not just a quality concern.

Semi-automatic tablet press machines offer mechanical controls and FDA-standard rejection, ideal for domestic production, medium batches, and operations where regulatory documentation requirements are lighter.

In pharmaceutical manufacturing, even 0.1% material wastage becomes a significant financial loss when the Active Pharmaceutical Ingredient (API) is expensive, as is the case with oncology, neurology, and specialty drugs.

21 CFR Part 11 is the FDA regulation that requires pharmaceutical manufacturers to maintain trustworthy electronic records and signatures, and it directly applies to your tablet press machine's control system.